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Summary
 Aim The aim of this article is to present a case of medulloblastoma in an adult patient 
aged 46 and the problems associated with its treatment.
 Case Description The authors present a case of medulloblastoma in a 46-year old male patient. 
The tumour, which is typically identiﬁ ed in childhood, is very rare in adults. The 
incidence rate, in individuals older than 16 years of age, is 0.05 per 100,000.
 Results The patient was subjected to combined therapy consisting of surgery and subsequent 
radiotherapy. This choice of management was successful – the patient has been fol-
lowed up since the completion of therapy and no relapses have been noted.
 Conclusions Based on this particular case, and the current literature, the authors discuss con-
temporary management methods in medulloblastoma.
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BACKGROUND
Medulloblastoma accounts for 20% of brain 
tumours arising in childhood [1]. Peak inci-
dence occurs between the 5  and 10  year of life. 
Medulloblastoma is very rare in adults and reports 
of its occurrence worldwide are scarce.
The most common site for medulloblastoma de-
velopment is the cerebellar vermis. From this lo-
cation the tumour penetrates into the fourth ven-
tricle, resulting in abnormalities in the ﬂ ow of 
cerebro-spinal ﬂ uid. Often the tumour surrounds 
and inﬁ ltrates the fourth ventricle, retracting the 
brachium pontis and subsequently spreading to-
wards the ventricular ﬂ oor. Spreading along the 
cerebro-spinal ﬂ uid routes, medulloblastoma may 
become disseminated within the central nervous 
system in 10–30% of pediatric patients.
Medulloblastoma belongs to the PNET group of 
tumours that originate from primitive, neuroep-
ithelial cells.
The tumour has two histological variants: clas-
sic and desmoplastic. The desmoplastic form is 
found in 20–40% of adult cases and in 10% of 
pediatric patients. [2–4] Some authors believe 
that – after comprehensive therapy – the prog-
nosis in medulloblastoma is more favorable in 
adults than in children [2].
Therapeutic management of medulloblastoma 
consists of an as-radical-as-possible excision of 
the tumour mass, followed by irradiation.
In children, chemotherapy is also applied, though 
routine chemotherapy in adult patients is still a 
matter of controversy in view of the very low in-
cidence of this malignancy, the resultant prob-
lems in ﬁ nding a uniform group of patients for 
clinical trials, and the slightly different course of 
the disease as compared to children.
AIM
The aim of this article is the presentation of a 
case of medulloblastoma in an adult patient 
aged 46 years, and the problems associated with 
its treatment.
CASE PRESENTATION
A 46-year old male had been complaining, for 2 
years, of severe, periodic headaches and dizziness, 
mostly in the afternoon. Diagnostic studies were 
carried out in the Departments of Neurosurgery 
and Neuropathology at the Jagiellonian University 
of Cracow. Computed tomography and magnetic 
resonance imaging of the head showed a tumour 
located in the posterior cranial fossa (Figure 1A,B). 
The patient was operated and a tumour of the 
vermis and cerebellar hemispheres was totally 
excised. Histopathologically the tumour was di-
agnosed as medulloblastoma. After surgery, the 
patient awoke but subsequently lost conscious-
ness. Computed tomography revealed an epidur-
al haematoma, which was promptly removed. One 
month later the patient was readmitted, owing to 
a considerable collection of cerebrospinal ﬂ uid at 
the surgical site, causing extracranial bulging. The 
patient was operated and an Orbis-Sigma ventricu-
lo-peritoneal valve was implanted. Following the 
shunt, the clinical and neurological status of the 
patient was found to be good. Subsequently, the 
man was referred to the Department of Oncology, 
Jagiellonian University of Cracow, where he was 
qualiﬁ ed for adjuvant radiotherapy. Radiation ther-
apy was planned using a three-dimensional compu-
ter-aided planning system. CT images were taken 
at 15mm intervals in the spinal cord area and eve-
ry 5mm for the cranial area (Figure 2). Next, PTV 
and the volume of tumour bed after surgery, with 
a 3cm margin, were outlined. Individual blocks, 
shielding healthy tissues, were planned and dose 
volume histograms were calculated. Irradiation 
was performed using an X-ray beam generated 
by a linear accelerator at the Radiotherapy Unit, 
University Children’s Hospital of Cracow. A pho-
ton beam was applied to the brain, using the two 
opposing ﬁ elds technique with shielding to the 
bones of the face, as well as to the spinal cord 
employing the three posterior ﬁ elds technique, 
with a moving gap between ﬁ elds. The dose was 
3500cGy administered in 21 fractions. A boost of 
2000cGy divided into 11 fractions was applied to 
the posterior cranial fossa, making the total dose 
5500cGy. For this patient, no multi-ﬁ eld confor-
mal techniques, for increasing the dose delivered 
to the tumour bed, were used. This was due to 
the fact that the PTV volume, including the tu-
mour bed with a 3cm margin, seemed to be quite 
large and choosing a more complicated radio-
therapy technique than the one used would not 
help with sparing the hypothalamic-pituitary sys-
tem or temporal lobes. In view of the signs of in-
tracranial pressure, anti-edematous agents were 
administered. The patient tolerated the therapy 
fairly well. At present, two years after completion 
of treatment his clinical and neurological status 
is good and he attends follow-up examinations 
at the Departments of Oncology and Neurology.
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DISCUSSION
Medulloblastoma is counted among childhood 
tumours. Its incidence among adults is low; the 
annual morbidity rate being approximately 0.05 
per 100 000 [1].
The mean age of such adult patients is approx-
imately 25 years (22.4–34.1). Cases in patients 
older than 40 are very rare. Our patient was 46 
years old at the time of diagnosis.
The tumour was located in the vermis as is of-
ten the case in children, although in adults it 
is more often situated in the cerebellar hemi-
spheres [3–5].
Standard management in adults lies in maximal-
ly radical surgery with subsequent irradiation. 
The elevated risks from surgery should however 
be taken into account in some cases, particular-
ly those involving large tumours. Postoperative 
complications such as haematoma or cerebrospi-
nal circulation disturbances can affect outcome. 
Besides, radiotherapy may be postponed owing 
to additional neurosurgical procedures – hae-
matoma removal, or cerebrospinal ﬂ uid shunt-
ing. In our case we experienced the mentioned 
complications, which affected neither neurolog-
ical outcome, nor signiﬁ cantly postponed fur-
ther treatment. In 1920, Cushing was the ﬁ rst 
to report surgical results obtained in children 
with medulloblastoma; the author managed to 
achieve 3-year survival in only one of 61 patients 
[6]. Between the years 1932 and 1947, Patterson 
employed postoperative radiotherapy of the en-
tire central nervous system, achieving 5-year sur-
vival in ﬁ ve of 12 children [6].
At present, the standard of management, both in 
older children and in adults, is combined therapy 
consisting of a maximally radical operation fol-
lowed by adjuvant irradiation of the entire cen-
tral nervous system. Irradiation uses doses of up 
to 3500cGy and the dose to the posterior cranial 
fossa is subsequently increased, reaching an ac-
cumulated dose of 5500cGy.
To achieve this purpose, a photon beam is ap-
plied to the entire brain and cervical spine up 
to the C3–C5 level using the two opposite ﬁ elds 
technique and shielding the facial skeleton; the 
beam is also applied to the spinal cord using the 
two or three posterior ﬁ elds technique with a mov-
ing gap mid-treatment, the dose being 3500cGy 
divided into 21 fractions; additionally, a dose of 
2000cGy divided into 11 fractions is applied to the 
posterior cranial fossa until a cumulative dose of 
5500cGy is reached. In certain cases, where the 
tumour was small and radically removed without 
Figure 2. Irradiation of the central nervous system. Dose 
distribution.
Figure 1A,B. Sagittal and axial T1 weighted MRI. A large tumour 
of the posterior cranial fossa localized in the vermis and cerebellar 
hemispheres.
A
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risk of relapse on the ﬁ eld border, it is possible 
to use conformal techniques for the tumour bed 
with a 3cm margin instead of posterior cranial 
fossa irradiation, which allows for sparing of the 
hypothalamus and pituitary gland. The best so-
lution is delineation of the tumour volume be-
fore surgery, with patient immobilized in the 
treatment position. However, on rare occasions 
in which intracranial hypertension is observed, 
the clinical status of the patient forces immedi-
ate surgical intervention.
In the late sixties, chemotherapy was ﬁ rst intro-
duced for children. Based on multi-center clini-
cal trials, chemotherapy has been demonstrated 
to improve therapeutic results in children with 
high-grade disease in so-called high-risk groups 
[7]. In low-risk groups, when tumours can be rad-
ically excised, their size is below 3cm and there 
are no metastases, the role of chemotherapy con-
tinues to be controversial [7].
In Poland, a protocol approved by the Polish 
Pediatric Group for CNS tumour treatment is ap-
plied; before radiotherapy in low-risk groups: vin-
cristine, etoposide, carboplatin are given, alter-
nating with cyclophosphamide, and in high-risk 
groups: ifosfamide is used instead of cyclophos-
phamide and cisplatin replaces carboplatin. After 
radiotherapy – 6 to 8 courses of cisplatin, vincris-
tine and CCNU are used. Routine postoperative 
chemotherapy is applied in younger children, be-
low 3 years of age, while radiotherapy is delayed 
until the child is at least three years old. In this 
group of patients, in view of the incomplete de-
velopment of their central nervous systems, post-
irradiation complications are the most severe.
Studies on introducing chemotherapy to the man-
agement of adult patients have not produced the 
expected results. The results were from studies 
into concurrent, or more frequently adjuvant 
chemotherapy, according to different protocols 
e.g. lomustine, vincristine and procarbazine (2,3), 
vincristine, lomustine and carmustine or ifosfa-
mide, cisplatin and vincristine (1), weekly vinc-
ristine during radiotherapy, followed by 8 cycles 
of cisplatin, lomustine and vincristine or, accord-
ing to the Pediatric Oncology Group guidelines, 
cisplatine/etoposide and cyclophosphamide/vin-
cristine followed by irradiation [8] and, in the 
poor-risk group adjuvant therapy with lomustine, 
vincristine and cisplatin [7].
Some authors report the beneﬁ cial effects of such 
therapy on therapeutic results [9,10], though the 
majority of investigators have failed to demon-
strate any statistically signiﬁ cant differences in 
the total and event-free survival rates [1,11–13]. 
In some reports the results were in fact poorer 
owing to an increased incidence of post-chem-
otherapy complications in adults in compari-
son to pediatric patients [1]. Investigations on 
the use of chemotherapy in adults continue, in-
cluding megachemotherapy with hematopoiet-
ic stem cell implantation, though the results re-
main controversial.[14].
The management of adult patients with medullob-
lastoma is, therefore, still based on surgery, as radi-
cal as possible, supplemented by irradiation of the 
entire central nervous system with increased doses 
applied to the site of the removed tumour.
When the above-described management is ap-
plied, the results achieved in adults with medul-
loblastoma are slightly better than in children [2]. 
As in the case of pediatric patients, adults may 
also be divided into low-risk and high-risk groups 
[15,16]. Event-free ﬁ ve-year survival rates amount 
to 40–65%, while ten-year survival is seen in ap-
proximately 20–40% of patients [10,12,13,15]. 
Total ﬁ ve-year survival rates are approximately 
60–80%, while ten-year survival is observed in 40–
50% of cases [3,10,12,17,18]. In low-risk groups 
of children, event-free ﬁ ve-year survival occurs in 
85%, while in high-risk groups the correspond-
ing rate is up to 50%. Ten-year survival is seen in 
approximately 30%. The outcome in adult pa-
tients shows considerable inter-centre variation 
and the reporting of precise data is hindered by 
the low numbers of investigated patients.
Relapses in adults occur after a mean period of 
30–40 months, following the completion of ther-
apy [1,13].
The most common site for relapses, in both chil-
dren and adults, is the posterior cranial fossa 
[1,3,8,15,16,19]. The dissemination of medul-
loblastoma along the cerebro-spinal ﬂ uid routes 
is slightly less common and is usually observed in 
cases of recurrent tumour at the original surgi-
cal site [3]. Metastases to remote sites such as the 
bones, lungs, pancreas and lymph nodes are spo-
radic. The mean survival time after detection of a 
relapse, and associated emergency treatment, is 77 
weeks (range of 44 to 89 weeks) [3,20]. Early de-
tection of tumour recurrence has a positive effect 
on therapeutic results. Some reports show that ap-
proximately one half of patients achieve remission 
following a second course of treatment [20].
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The most commonly applied management, in 
cases of relapse in children, is second-line chem-
otherapy, or megachemotherapy, using haemat-
opoietic stem cell implantation. The outcome is 
poor and the majority of patients do not survive 
past 24 months. In adult patients with relapses 
one may consider the use of chemotherapy when 
chances of success from irradiation have already 
been exhausted [14]. Re-operation of the tumour 
is controversial, especially in the irradiated re-
gion. The outcome is positively affected by low 
staging of clinical disease advancement prior to 
treatment, desmoplastic histological tumour type, 
completeness of surgery, a total dose - applied to 
the entire central nervous system - of at least 35Gy 
(and at least 54Gy to the posterior cranial fossa) 
[1,2,19,21], and – according to some investiga-
tors – female sex and older age [4,22].
Data on the incidence of medulloblastoma in 
adults is scarce. Thus, it is difﬁ cult to collect a uni-
form group of patients. In Poland, Skołyszewski 
and Gliński described a series of 13 adult patients 
with medulloblastoma, ranging in age from 16 
to 52 years, with a mean age of 22.4 years. The 
authors achieved event-free ﬁ ve-year survivals in 
62% of cases [23]. Based on data from the liter-
ature regarding the incidence of medulloblas-
toma in adults, one may claim that the 46-year 
old patient we describe here is a very rare case 
[24,25]. We assume that the applied therapeu-
tic method was optimal, though ultimate evalu-
ation requires prolonged follow-up.
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